Tackling the remaining challenges of multiple sclerosisWith Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond Share XTackling the remaining challenges of multiple sclerosishttps://pharmaphorum.com/r-d/views-analysis-r-d/tackling-the-remaining-challenges-of-multiple-sclerosis/